KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $6.0 million.

  • Bionano Genomics' Accounts Payables fell 3114.94% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 3114.94%. This contributed to the annual value of $7.0 million for FY2024, which is 3295.45% down from last year.
  • Latest data reveals that Bionano Genomics reported Accounts Payables of $6.0 million as of Q3 2025, which was down 3114.94% from $6.2 million recorded in Q2 2025.
  • Bionano Genomics' 5-year Accounts Payables high stood at $15.8 million for Q1 2023, and its period low was $2.2 million during Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $8.7 million (2024), whereas its average is $8.8 million.
  • As far as peak fluctuations go, Bionano Genomics' Accounts Payables skyrocketed by 26754.27% in 2021, and later crashed by 4339.25% in 2024.
  • Over the past 5 years, Bionano Genomics' Accounts Payables (Quarter) stood at $10.8 million in 2021, then increased by 16.39% to $12.5 million in 2022, then dropped by 17.15% to $10.4 million in 2023, then tumbled by 32.95% to $7.0 million in 2024, then dropped by 13.96% to $6.0 million in 2025.
  • Its Accounts Payables stands at $6.0 million for Q3 2025, versus $6.2 million for Q2 2025 and $6.6 million for Q1 2025.